Drug Search Results
Using advanced filters...
Advanced Search [+]

CMAB-009

Alternative Names: cmab-009, cmab009, cmab 009
Clinical Status: Active
Latest Update: 2025-06-29
Latest Update Note: Clinical Trial Update

Product Description

novel recombinant human/mouse chimeric epidermal growth factor receptor (EGFR) monoclonal antibody

Mechanisms of Action: EGFR Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Shanghai Zhangjiang Biotechnology Limited Company
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CMAB-009

Countries in Clinic: China

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Colorectal Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

CTR20170701

P3

Active, not recruiting

Colorectal Cancer

None

2025-04-29

Patient Enrollment|Start Date|Treatments|Trial Status

Recent News Events